Daniel A. Haber, MD, PhD
Director, Cancer Center
Dr. Daniel Haber is Director of Massachusetts General Hospital (MGH) Cancer Center and the Isselbacher/Schwartz Professor of Oncology at Harvard Medical School. He received his MD and PhD degrees at Stanford in 1983, completed an internal medicine residency at MGH, clinical oncology training at the Dana-Farber Cancer Institute, and a postdoctoral research fellowship at MIT. He joined the faculty of Harvard Medical School in 1991. Dr. Haber’s numerous awards include a MERIT Award from the National Cancer Institute, a Dream Team award from the Prostate Cancer Foundation, and the Richard and Hinda Rosenthal Memorial Award from the American Association for Cancer Research (AACR). He was appointed to the Howard Hughes Medical Institute in 2008 and was elected to the Institute of Medicine in 2009.
Dr. Haber’s research has focused primarily in the field of cancer genetics, resulting in discoveries on the origin of the pediatric kidney cancer Wilms tumor, genetic predispositions to breast cancer, and mutations that define a subset of “non-smoker” lung cancers that are uniquely sensitive to targeted new therapies. In collaboration with MGH bioengineer Dr. Mehmet Toner, Dr. Haber’s laboratory has developed a novel technology for isolating rare circulating tumor cells (CTCs) from the blood of cancer patients—a tool that may have profound implications for early diagnosis of cancer and for noninvasive molecular profiling of cancers during therapy.